申请人:Rigel Pharmaceuticals, Inc.
公开号:US07491732B2
公开(公告)日:2009-02-17
The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.
该发明涵盖了具有I-V式的化合物,以及使用这些化合物在调节JAK通路或抑制JAK激酶,特别是JAK3,在治疗可能具有治疗作用的疾病中的组合物和方法。